Q32 Bio vs Xilio Therapeutics
QTTB and XLO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How QTTB and XLO compare
Q32 Bio is the larger company, worth 5.9 times as much as Xilio Therapeutics ($257M against $43.6M).
Xilio Therapeutics scores higher on the StockData Score (11 against 8 for Q32 Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | QTTB | XLO |
|---|---|---|
| Size and price | ||
| Market cap | $257M | $43.6M |
| Share price | $8.63 | $7.54 |
| Change, 1 year | 300% | −23.8% |
| Change, 5 years | −90.8% | −97.3% |
| Beta (5Y) | −0.98 | 0.03 |
| Employees | 24 | 76 |
| StockData Score | ||
| Total score | 8 | 11 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 1 | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 0.7× |
| P/B | 2.4× | 0.6× (better) |
| EV/EBITDA | 7.0× | – |
| FCF yield | – | −141% |
| Fair value | – | $37.97 |
| Margin of safety | – | 80.1% |
| Growth | ||
| Revenue growth (TTM) | – | 327% |
| Revenue growth, 5Y average | 81.9% | – |
| Profitability | ||
| Operating margin | – | −48.9% |
| Net margin | – | −34.1% |
| FCF margin | – | −95.6% |
| Return on equity | 72.1% (better) | −55.0% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 20.30 (better) | 4.25 |
| Altman Z-score | 14.49 (better) | −3.02 |
| Piotroski F-score | 4 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −4.0% | – |
| Shareholder yield | −4.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 74.6% | 58.9% |
| Held by insiders | 28.9% | – |
| Insider net buying, 12 months | $29.5M (better) | $38.3K |
| Short interest, % of float | 26.4% | – |
Go deeper
- QTTB stock overview
- QTTB income statement
- QTTB valuation and score
- XLO stock overview
- XLO income statement
- XLO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.